

Special Issue

New Advances in Pharmacologic and Non- pharmacologic Therapy in Heart Failure and Heart Transplant

Message from the Guest Editors

In recent years, treatment strategies for patients with heart failure have expanded with new pharmacological (sacubitril/valsartan, SGLT2-i, vericiguat, omecamtiv mecarbil, ferric carboxymaltose) and non-pharmacological (cardiac contractility modulation, baroreceptor stimulation) options. Despite these advances, mortality and morbidity of heart failure patients is still high. In the upcoming ESC 2021 guidelines for the diagnosis and treatment of acute and chronic heart failure, the current challenge is to develop targeted therapies according to the etiology (e.g., amyloidosis, peripartum cardiomyopathy, inflammatory dilated cardiomyopathy), and the clinical phenotype of the patient (renal failure, bradycardia, low arterial pressure) and the presence of comorbidities (iron deficiency, sleep-disordered breathing, and diabetes). This tailored approach aims to prevent functional deterioration and ultimately reduce morbidity and mortality. The purpose of this Special Issue is to highlight new opportunities for improved treatments in heart failure.

Guest Editors

Dr. Daniele Masarone

Heart Failure Unit, Department of Cardiology, AORN dei Colli-Monaldi Hospital, Naples, Italy

Dr. Carlo Lombardi

Cardiology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy

Deadline for manuscript submissions

closed (20 December 2023)



Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 5.7
Indexed in PubMed



mdpi.com/si/98504

Journal of Clinical Medicine
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jcm@mdpi.com

mdpi.com/journal/

[jcm](https://mdpi.com/journal/)





Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 5.7
Indexed in PubMed



mdpi.com/journal/

[jcm](https://jcm.mdpi.com)



About the Journal

Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's* (JCM) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

Editors-in-Chief

Prof. Dr. Emmanuel Andrès

Internal Medicine Department, University Hospital Strasbourg, 67000
Strasbourg, France

Prof. Dr. Kent Doi

Department of Acute Care Medicine, University of Tokyo, Tokyo, Japan

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1
(General Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.3 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2024).